journal
MENU ▼
Read by QxMD icon Read
search

Lancet Infectious Diseases

journal
https://www.readbyqxmd.com/read/30001857/switch-in-a-childhood-pneumococcal-vaccination-programme-from-pcv13-to-pcv10-a-defendable-approach
#1
LETTER
Stefanie Desmet, Jan Verhaegen, Marc Van Ranst, Willy Peetermans, Katrien Lagrou
No abstract text is available yet for this article.
July 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/30001856/interpretation-of-the-switch-in-a-childhood-pneumococcal-vaccination-programme-from-pcv13-to-pcv10-in-belgium
#2
LETTER
Patricia Izurieta, Thomas Breuer
No abstract text is available yet for this article.
July 9, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29983342/advancing-the-public-health-applications-of-chlamydia-trachomatis-serology
#3
REVIEW
Sarah C Woodhall, Rachel J Gorwitz, Stephanie J Migchelsen, Sami L Gottlieb, Patrick J Horner, William M Geisler, Catherine Winstanley, Katrin Hufnagel, Tim Waterboer, Diana L Martin, Wilhelmina M Huston, Charlotte A Gaydos, Carolyn Deal, Magnus Unemo, J Kevin Dunbar, Kyle Bernstein
Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease...
July 5, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29980383/laboratory-medicine-in-africa-since-2008-then-now-and-the-future
#4
REVIEW
John N Nkengasong, Francois-Xavier Mbopi-Keou, Rosanna W Peeling, Katy Yao, Clement E Zeh, Miriam Schneidman, Renuka Gadde, Alash'le Abimiku, Philip Onyebujoh, Deborah Birx, Shannon Hader
The Maputo Declaration of 2008 advocated for commitment from global stakeholders and national governments to prioritise support and harmonisation of laboratory systems through development of comprehensive national laboratory strategies and policies in sub-Saharan Africa. As a result, HIV laboratory medicine in Africa has undergone a transformation, and substantial improvements have been made in diagnostic services, networks, and institutions, including the development of a competent workforce, introduction of point-of-care diagnostics, and innovative quality improvement programmes that saw more than 1100 laboratories enrolled and 44 accredited to international standards...
July 3, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29958831/corrections
#5
(no author information available yet)
No abstract text is available yet for this article.
June 26, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29935779/unanswered-questions-about-the-1918-influenza-pandemic-origin-pathology-and-the-virus-itself
#6
REVIEW
John S Oxford, Douglas Gill
The influenza epidemic of 1918 represented the greatest failure of medical science in the 20th century. Fortunately, research throughout subsequent years has been making amends. Some studies have applied RT-PCR to the tissue samples from that time, whereas others have reconstructed the pathogen in its virulent state. But the resurrection of the 1918 influenza virus leaves questions unanswered: although more virulent than contemporary H1N1 epidemic viruses in animal models, this increased virulence of the 1918 influenza virus is not sufficient to have been the sole cause of the high mortality rates recorded in humans during the epidemic...
June 20, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29934112/unexpected-outbreaks-of-arbovirus-infections-lessons-learned-from-the-pacific-and-tropical-america
#7
REVIEW
Didier Musso, Alfonso J Rodriguez-Morales, José Eduardo Levi, Van-Mai Cao-Lormeau, Duane J Gubler
Pandemic arboviruses have emerged as a major global health problem in the past four decades. Predicting where and when the next arbovirus epidemic will occur is a challenge, but history suggests that arboviral black swan events (epidemics that are difficult to predict and that have an extreme effect) will continue to occur as urban growth and globalisation expand. We briefly review unexpected arbovirus epidemics that have occurred in the past 50 years, with emphasis on the American and Pacific regions, to illustrate their unpredictability, and to highlight the need for improved global preparedness, including laboratory-based surveillance, prevention, and control programmes...
June 19, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29929783/safety-pharmacokinetics-and-immunogenicity-of-a-co-formulated-cocktail-of-three-human-monoclonal-antibodies-targeting-ebola-virus-glycoprotein-in-healthy-adults-a-randomised-first-in-human-phase-1-study
#8
Sumathi Sivapalasingam, Mohamed Kamal, Rabih Slim, Romana Hosain, Weiping Shao, Randall Stoltz, Joseph Yen, Laura G Pologe, Yuan Cao, Michael Partridge, Giane Sumner, Leah Lipsich
BACKGROUND: REGN3470-3471-3479 is a co-formulated cocktail of three human monoclonal antibodies targeting three non-overlapping epitopes on Ebola virus. We investigated safety, tolerability, pharmacokinetics, and anti-drug antibodies in healthy adults. METHODS: This randomised, double-blind, placebo-controlled, dose-escalation study was done at a phase 1 unit in the USA. Healthy adults, aged 18-60 years, with a body-mass index of 18·0-30·0 kg/m2 were randomly assigned (3:1) to receive a single intravenous dose of REGN3470-3471-3479 or placebo on day 1 (baseline) in one of the four sequential ascending intravenous dose cohorts (3 mg/kg, 15 mg/kg, 60 mg/kg, and 150 mg/kg)...
June 18, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29929782/corrections
#9
(no author information available yet)
No abstract text is available yet for this article.
June 18, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29929781/following-the-roadmap-toward-an-effective-ebola-virus-treatment
#10
Trina Racine
No abstract text is available yet for this article.
June 18, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29887371/risk-of-sudden-unexplained-death-after-use-of-dihydroartemisinin-piperaquine-for-malaria-a-systematic-review-and-bayesian-meta-analysis
#11
Xin Hui S Chan, Yan Naung Win, Laura J Mawer, Jireh Y Tan, Josep Brugada, Nicholas J White
BACKGROUND: Dihydroartemisinin-piperaquine is an effective and well tolerated artemisinin-based combination therapy that has been assessed extensively for the prevention and treatment of malaria. Piperaquine, similar to several structurally related antimalarials currently used, can prolong cardiac ventricular repolarisation duration and the electrocardiographic QT interval, leading to concerns about its proarrhythmic potential. We aimed to assess the risk of potentially lethal iatrogenic ventricular arrhythmias in individuals receiving dihydroartemisinin-piperaquine...
June 18, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29914800/the-respiratory-syncytial-virus-vaccine-landscape-lessons-from-the-graveyard-and-promising-candidates
#12
REVIEW
Natalie I Mazur, Deborah Higgins, Marta C Nunes, José A Melero, Annefleur C Langedijk, Nicole Horsley, Ursula J Buchholz, Peter J Openshaw, Jason S McLellan, Janet A Englund, Asuncion Mejias, Ruth A Karron, Eric Af Simões, Ivana Knezevic, Octavio Ramilo, Pedro A Piedra, Helen Y Chu, Ann R Falsey, Harish Nair, Leyla Kragten-Tabatabaie, Anne Greenough, Eugenio Baraldi, Nikolaos G Papadopoulos, Johan Vekemans, Fernando P Polack, Mair Powell, Ashish Satav, Edward E Walsh, Renato T Stein, Barney S Graham, Louis J Bont
The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development...
June 15, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29909070/dsm265-a-novel-drug-for-single-dose-cure-of-plasmodium-falciparum-malaria
#13
Sabine Bélard, Michael Ramharter
No abstract text is available yet for this article.
June 13, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29909069/antimalarial-activity-of-single-dose-dsm265-a-novel-plasmodium-dihydroorotate-dehydrogenase-inhibitor-in-patients-with-uncomplicated-plasmodium-falciparum-or-plasmodium-vivax-malaria-infection-a-proof-of-concept-open-label-phase-2a-study
#14
Alejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, Juan-Carlos Hinojosa, Nicola Kerr, Maria Rosario, Stephen Toovey, Robert H Arch, Margaret A Phillips, Felix D Rozenberg, Jade Bath, Caroline L Ng, Annie N Cowell, Elizabeth A Winzeler, David A Fidock, Mark Baker, Jörg J Möhrle, Rob Hooft van Huijsduijnen, Nathalie Gobeau, Nada Araeipour, Nicole Andenmatten, Thomas Rückle, Stephan Duparc
BACKGROUND: DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection. METHODS: This proof-of-concept, open-label, phase 2a study was conducted at the Asociación Civil Selva Amazónica in Iquitos, Peru...
June 13, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29907497/corrections
#15
(no author information available yet)
No abstract text is available yet for this article.
June 12, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29891332/experimental-infection-of-human-volunteers
#16
REVIEW
Meta Roestenberg, Marie-Astrid Hoogerwerf, Daniela M Ferreira, Benjamin Mordmüller, Maria Yazdanbakhsh
Controlled human infection (CHI) trials, in which healthy volunteers are experimentally infected, can accelerate the development of novel drugs and vaccines for infectious diseases of global importance. The use of CHI models is expanding from around 60 studies in the 1970s to more than 120 publications in this decade, primarily for influenza, rhinovirus, and malaria. CHI trials have provided landmark data for several registered drugs and vaccines, and have generated unprecedented scientific insights. Because of their invasive nature, CHI studies demand critical ethical review according to established frameworks...
June 8, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29887370/reappraising-the-cardiosafety-of-dihydroartemisinin-piperaquine
#17
Pere Millat-Martínez, Quique Bassat
No abstract text is available yet for this article.
June 7, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29884573/bloodstream-infection-and-occlusion-of-central-venous-catheters-in-children
#18
Claire M Rickard, Amanda J Ullman
No abstract text is available yet for this article.
June 5, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29884572/treatment-and-secondary-prophylaxis-with-ethanol-lock-therapy-for-central-line-associated-bloodstream-infection-in-paediatric-cancer-a-randomised-double-blind-controlled-trial
#19
Joshua Wolf, Tom G Connell, Kim J Allison, Li Tang, Julie Richardson, Kristen Branum, Eloise Borello, Jeffrey E Rubnitz, Aditya H Gaur, Hana Hakim, Yin Su, Sara M Federico, Francoise Mechinaud, Randall T Hayden, Paul Monagle, Leon J Worth, Nigel Curtis, Patricia M Flynn
BACKGROUND: Central line-associated bloodstream infections (CLABSIs) affect about 25% of children with cancer, and treatment failure is common. Adjunctive ethanol lock therapy might prevent treatment failure but high-quality evidence is scarce. We evaluated ethanol lock therapy as treatment and secondary prophylaxis for CLABSI in children with cancer or haematological disorders. METHODS: This randomised, double-blind, placebo-controlled superiority trial, with two interim futility and efficacy analyses (done when the first 46 and 92 evaluable participants completed study requirements), was done at two paediatric hospitals in the USA and Australia...
June 5, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29880302/enhanced-terminal-room-disinfection-and-the-need-for-multimodal-collaboration
#20
Matthew P Crotty, Marie H Wilson
No abstract text is available yet for this article.
June 4, 2018: Lancet Infectious Diseases
journal
journal
20187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"